{
    "clinical_study": {
        "@rank": "168118", 
        "arm_group": [
            {
                "arm_group_label": "A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)", 
                "arm_group_type": "Experimental", 
                "description": "Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose"
            }, 
            {
                "arm_group_label": "A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin", 
                "arm_group_type": "Experimental", 
                "description": "Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose"
            }, 
            {
                "arm_group_label": "B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)", 
                "arm_group_type": "Experimental", 
                "description": "Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose"
            }, 
            {
                "arm_group_label": "B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose"
            }, 
            {
                "arm_group_label": "C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin", 
                "arm_group_type": "Experimental", 
                "description": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose"
            }, 
            {
                "arm_group_label": "C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin", 
                "arm_group_type": "Experimental", 
                "description": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate whether the pharmacokinetics (body\n      concentrations/metabolism of the drug) of Saxagliptin  and Dapagliflozin are affected when\n      they are administered together"
        }, 
        "brief_title": "Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral.", 
                            "title": "A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral.", 
                            "title": "A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral", 
                            "title": "B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)"
                        }, 
                        {
                            "@group_id": "B4", 
                            "description": "Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral.", 
                            "title": "B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin"
                        }, 
                        {
                            "@group_id": "B5", 
                            "description": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets,Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral.", 
                            "title": "C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin"
                        }, 
                        {
                            "@group_id": "B6", 
                            "description": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral.", 
                            "title": "C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin"
                        }, 
                        {
                            "@group_id": "B7", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B5", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B6", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B7", 
                                                "@value": "42"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B4", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B5", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B6", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B7", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "7"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "7"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "7"
                                                }, 
                                                {
                                                    "@group_id": "B4", 
                                                    "@value": "7"
                                                }, 
                                                {
                                                    "@group_id": "B5", 
                                                    "@value": "7"
                                                }, 
                                                {
                                                    "@group_id": "B6", 
                                                    "@value": "7"
                                                }, 
                                                {
                                                    "@group_id": "B7", 
                                                    "@value": "42"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B4", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B5", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B6", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B7", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "6.47", 
                                                "@value": "36.1"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "5.02", 
                                                "@value": "28.7"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "6.99", 
                                                "@value": "27.7"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@spread": "6.51", 
                                                "@value": "32.0"
                                            }, 
                                            {
                                                "@group_id": "B5", 
                                                "@spread": "5.74", 
                                                "@value": "34.4"
                                            }, 
                                            {
                                                "@group_id": "B6", 
                                                "@spread": "7.95", 
                                                "@value": "33.3"
                                            }, 
                                            {
                                                "@group_id": "B7", 
                                                "@spread": "6.81", 
                                                "@value": "32.0"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "2"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "2"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "2"
                                                }, 
                                                {
                                                    "@group_id": "B4", 
                                                    "@value": "3"
                                                }, 
                                                {
                                                    "@group_id": "B5", 
                                                    "@value": "2"
                                                }, 
                                                {
                                                    "@group_id": "B6", 
                                                    "@value": "2"
                                                }, 
                                                {
                                                    "@group_id": "B7", 
                                                    "@value": "13"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "5"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "5"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "5"
                                                }, 
                                                {
                                                    "@group_id": "B4", 
                                                    "@value": "4"
                                                }, 
                                                {
                                                    "@group_id": "B5", 
                                                    "@value": "5"
                                                }, 
                                                {
                                                    "@group_id": "B6", 
                                                    "@value": "5"
                                                }, 
                                                {
                                                    "@group_id": "B7", 
                                                    "@value": "29"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B5", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B6", 
                                                "@value": "7"
                                            }, 
                                            {
                                                "@group_id": "B7", 
                                                "@value": "42"
                                            }
                                        ]
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "0.187", 
                                                "@value": "1.90"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "0.145", 
                                                "@value": "1.92"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "0.208", 
                                                "@value": "1.91"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@spread": "0.170", 
                                                "@value": "1.95"
                                            }, 
                                            {
                                                "@group_id": "B5", 
                                                "@spread": "0.166", 
                                                "@value": "1.94"
                                            }, 
                                            {
                                                "@group_id": "B6", 
                                                "@spread": "0.108", 
                                                "@value": "1.85"
                                            }, 
                                            {
                                                "@group_id": "B7", 
                                                "@spread": "0.160", 
                                                "@value": "1.91"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "description": "Body surface area was measured in meters squared (m^2) prior to first dose of study drug (Day -1).", 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Body Surface Area (m^2)", 
                            "units": "m^2"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "12.250", 
                                                "@value": "77.94"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "8.100", 
                                                "@value": "78.94"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "14.589", 
                                                "@value": "76.01"
                                            }, 
                                            {
                                                "@group_id": "B4", 
                                                "@spread": "11.903", 
                                                "@value": "80.73"
                                            }, 
                                            {
                                                "@group_id": "B5", 
                                                "@spread": "11.223", 
                                                "@value": "79.64"
                                            }, 
                                            {
                                                "@group_id": "B6", 
                                                "@spread": "6.404", 
                                                "@value": "71.71"
                                            }, 
                                            {
                                                "@group_id": "B7", 
                                                "@spread": "10.813", 
                                                "@value": "77.50"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "description": "Body weight was measured in kilograms (k) prior to first dose of study drug (Day -1).", 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Body Weight (kg)", 
                            "units": "kg"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "0.867", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.026", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "0.943"
                            }
                        }, 
                        "description": "The geometric mean of the maximum observed plasma concentration (Cmax) is presented below; serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h,and 60 h postdose, relative to dosing on Day 1 in each cross over period and these data are summarized in the Pharmacokinetic (PK) parameter of Cmax presented here. Plasma samples were analyzed for dapagliflozin by High Performance Liquid chromatography\u2013Mass Spectrometry (HPLC-MS/MS) using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Dapagliflozin Cmax was derived from plasma concentration versus time data using a non-compartmental method, using a validated PK analysis program \u2122. Actual sampling times were used for PK calculations. Cmax was reported in ng/mL.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg Dapagliflozin", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "41"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "23", 
                                                        "@value": "133"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "27", 
                                                        "@value": "125"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "The geometric mean of the maximum observed plasma concentration (Cmax) is presented below; serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h,and 60 h postdose, relative to dosing on Day 1 in each cross over period and these data are summarized in the Pharmacokinetic (PK) parameter of Cmax presented here. Plasma samples were analyzed for dapagliflozin by High Performance Liquid chromatography\u2013Mass Spectrometry (HPLC-MS/MS) using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Dapagliflozin Cmax was derived from plasma concentration versus time data using a non-compartmental method, using a validated PK analysis program \u2122. Actual sampling times were used for PK calculations. Cmax was reported in ng/mL.", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "Pharmacokinetic (PK) Evaluable: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte. One participant in the ACB treatment sequence withdrew consent after having received all 3 treatments; this participant did not provide 36-, 48-, or 60-hour samples in Period 3 (Treatment B).", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0 h to 60 h post dose) in each period", 
                        "title": "Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population", 
                        "type": "Primary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "0.961", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.008", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "Treatment B versus C in AUC(INF). The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ration of adjusted geometric mean", 
                                "param_value": "0.984"
                            }
                        }, 
                        "description": "AUC(INF) is area under the plasma concentration-time curve from time 0 extrapolated to infinity. Serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL).   Actual sampling times were used for PK calculations. AUC(INF) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg Dapagliflozin.", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "41"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "23", 
                                                        "@value": "547"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "20", 
                                                        "@value": "539"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "AUC(INF) is area under the plasma concentration-time curve from time 0 extrapolated to infinity. Serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL).   Actual sampling times were used for PK calculations. AUC(INF) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                                    "units": "ng*h/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte. One participant in the ACB treatment sequence withdrew consent after having received all 3 treatments; this participant did not provide 36-, 48-, or 60-hour samples in Period 3 (Treatment B).", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.   Actual sampling times were used for PK calculations. Tmax was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg Dapagliflozin.", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "41"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "2.02", 
                                                        "@value": "1.00"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@lower_limit": "0.50", 
                                                        "@upper_limit": "2.00", 
                                                        "@value": "1.00"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.   Actual sampling times were used for PK calculations. Tmax was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours.", 
                                    "dispersion": "Full Range", 
                                    "param": "Median", 
                                    "title": "Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population", 
                                    "units": "hours"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte. 1 participant (ACB treatment sequence) withdrew consent after having received all 3 treatments and did not provide 36-, 48-, or 60-hour samples in Period 3 (Treatment B). This did not impact T-HALF.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "0.966", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.014", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "Treatment B versus C in AUC(0-T). The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "0.990"
                            }
                        }, 
                        "description": "AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method).  Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL).  Actual sampling times were used for PK calculations. AUC(0-T) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg Dapagliflozin.", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "41"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "23", 
                                                        "@value": "529"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "19", 
                                                        "@value": "523"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method).  Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL).  Actual sampling times were used for PK calculations. AUC(0-T) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin", 
                                    "units": "ng*h/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte. One participant in the ACB treatment sequence withdrew consent after having received all 3 treatments; this participant did not provide 36-, 48-, or 60-hour samples in Period 3 (Treatment B).", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.   Actual sampling times were used for PK calculations. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg Dapagliflozin", 
                                    "title": "10mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "7.32", 
                                                        "@value": "15.9"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "4.81", 
                                                        "@value": "13.8"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.   Actual sampling times were used for PK calculations. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                                    "units": "hours"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte. 1 participant (ACB treatment sequence) withdrew consent after having received all 3 treatments and did not provide 36-, 48-, or 60-hour samples in Period 3 (Treatment B). This did not impact T-HALF.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "0.883", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "0.972", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the Pharmacokinetics of saxagliptin. The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "0.927"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography\u2013Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). Cmax for Saxagliptin was derived from plasma concentration versus time data using a validated PK analysis program \u2122 and was measured in nanograms per milliliter (ng/mL).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: Single dose Saxagliptin 5mg, Tablet, Oral.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "31", 
                                                        "@value": "23.6"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "33", 
                                                        "@value": "21.9"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography\u2013Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). Cmax for Saxagliptin was derived from plasma concentration versus time data using a validated PK analysis program \u2122 and was measured in nanograms per milliliter (ng/mL).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.  Actual sampling times were used for PK calculations. CLT/F was calculated as Dose/AUC(INF)and was measured in milliliters per minute  (mL/min).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg Dapagliflozin.", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "41"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "24", 
                                                        "@value": "305"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "20", 
                                                        "@value": "309"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.  Actual sampling times were used for PK calculations. CLT/F was calculated as Dose/AUC(INF)and was measured in milliliters per minute  (mL/min).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                                    "units": "mL/min"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte. One participant in the ACB treatment sequence withdrew consent after having received all 3 treatments; this participant did not provide 36-, 48-, or 60-hour samples in Period 3 (Treatment B).", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "1.004", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.109", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the Pharmacokinetics of 5-OH saxagliptin (metabolite of saxagliptin). The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "1.055"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). Actual sampling times were used for PK calculations. Cmax for 5-OH Saxagliptin (the major active metabolite of Saxagliptin) was derived from plasma concentration versus time data using a validated PK analysis program \u2122 and was measured in ng/mL.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg dapagliflozin.", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "30", 
                                                        "@value": "47.0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "27", 
                                                        "@value": "49.6"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). Actual sampling times were used for PK calculations. Cmax for 5-OH Saxagliptin (the major active metabolite of Saxagliptin) was derived from plasma concentration versus time data using a validated PK analysis program \u2122 and was measured in ng/mL.", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                                    "units": "ng/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "0.960", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.022", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the Pharmacokinetics of saxagliptin. The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "0.991"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography\u2013Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(0-T), the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: single dose of Saxagliptin 5mg, Tablet, Oral.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "23", 
                                                        "@value": "87.8"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "23", 
                                                        "@value": "87.0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography\u2013Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(0-T), the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                                    "units": "ng*h/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                        "type": "Primary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "0.961", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.022", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the Pharmacokinetics of saxagliptin. The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "0.991"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: single dose of Saxagliptin 5mg, Tablet, Oral.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "23", 
                                                        "@value": "89.0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "23", 
                                                        "@value": "88.2"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                                    "units": "ng*h/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                        "type": "Primary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "1.058", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.113", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the Pharmacokinetics of 5-OH saxagliptin (metabolite). The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "1.085"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method)and was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122. AUC (0-T) was measured in nanograms*hours per milliliter (ng*h/mL).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg dapagliflozin.", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "22", 
                                                        "@value": "267"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "22", 
                                                        "@value": "289"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method)and was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122. AUC (0-T) was measured in nanograms*hours per milliliter (ng*h/mL).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population", 
                                    "units": "ng*h/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "1.058", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.113", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the Pharmacokinetics of 5-OH saxagliptin (metabolite). The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "ratio of adjusted geometric mean", 
                                "param_value": "1.085"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment B: Single dose oral tablet of 10 mg dapagliflozin.", 
                                    "title": "10 mg Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "22", 
                                                        "@value": "273"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "22", 
                                                        "@value": "296"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                                    "units": "ng*h/mL"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "0.960", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.030", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the Pharmacokinetics of saxagliptin total active moiety. The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "0.994"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Cmax of saxagliptin total active moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin) was derived from the plasma concentration versus time profile for the saxagliptin total active moiety.  Measurement was in nano Molars (nM).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "20", 
                                                        "@value": "138"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "21", 
                                                        "@value": "137"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Cmax of saxagliptin total active moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin) was derived from the plasma concentration versus time profile for the saxagliptin total active moiety.  Measurement was in nano Molars (nM).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                                    "units": "nM"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "ci_lower_limit": "1.029", 
                                "ci_n_sides": "2-Sided", 
                                "ci_percent": "90", 
                                "ci_upper_limit": "1.064", 
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "groups_desc": "This analysis assesses the effect of concomitant administration of dapagliflozin on the AUC(0-T) of saxagliptin total active moiety. The statistical model includes treatment and period as fixed effects and measurements within each participant as repeated measurements. The adjusted geometric means are from the mixed model.", 
                                "non_inferiority": "No", 
                                "param_type": "Ratio of adjusted geometric mean", 
                                "param_value": "1.046"
                            }
                        }, 
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. AUC(INF) is area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) and both were derived from the plasma concentration versus time profile using a validated PK analysis program \u2122. Total moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin), AUC(0-T)and AUC(INF) were measured in nano Molars*hours (nM*h).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "15", 
                                                            "@value": "702"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "15", 
                                                            "@value": "735"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "AUC(INF) for Saxagliptin Total Active Moiety"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "15", 
                                                            "@value": "694"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "15", 
                                                            "@value": "727"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "AUC(0-T) for Saxagliptin Total Active Moiety"
                                            }
                                        ]
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. AUC(INF) is area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) and both were derived from the plasma concentration versus time profile using a validated PK analysis program \u2122. Total moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin), AUC(0-T)and AUC(INF) were measured in nano Molars*hours (nM*h).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "AUC(INF) and AUC(0-T) of the Saxagliptin Total Active Moiety From a Single Dose 5 mg Saxagliptin Versus AUC(INF) and AUC(0-T) of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                                    "units": "nM*h"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "AUC(INF) and AUC(0-T) of the Saxagliptin Total Active Moiety From a Single Dose 5 mg Saxagliptin Versus AUC(INF) and AUC(0-T) of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin and 5-OH by LC-MS/MS using a validated method. Tmax was derived from the plasma concentration versus time profile for study drug and was measured in hours (h). Saxagliptin was the drug, 5-OH saxagliptin was the metabolite, and Saxagliptin total Active Moiety was molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: Single saxagliptin 5mg, Tablet, Oral.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "0.50", 
                                                            "@upper_limit": "2.00", 
                                                            "@value": "0.50"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "0.50", 
                                                            "@upper_limit": "2.00", 
                                                            "@value": "1.00"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Tmax of Saxagliptin"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "1.00", 
                                                            "@upper_limit": "2.00", 
                                                            "@value": "1.50"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "1.00", 
                                                            "@upper_limit": "3.00", 
                                                            "@value": "1.50"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Tmax of 5-OH Saxagliptin"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "0.50", 
                                                            "@upper_limit": "2.00", 
                                                            "@value": "1.00"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "0.50", 
                                                            "@upper_limit": "2.00", 
                                                            "@value": "1.00"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Tmax of Saxagliptin Total Active Moiety"
                                            }
                                        ]
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin and 5-OH by LC-MS/MS using a validated method. Tmax was derived from the plasma concentration versus time profile for study drug and was measured in hours (h). Saxagliptin was the drug, 5-OH saxagliptin was the metabolite, and Saxagliptin total Active Moiety was molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin.", 
                                    "dispersion": "Full Range", 
                                    "param": "Median", 
                                    "title": "Tmax of Saxagliptin, 5-OH Saxagliptin, Saxagliptin Total Active Moiety From a Single Dose of Saxagliptin Versus Tmax of Saxagliptin, 5-OH, Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                                    "units": "h"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Tmax of Saxagliptin, 5-OH Saxagliptin, Saxagliptin Total Active Moiety From a Single Dose of Saxagliptin Versus Tmax of Saxagliptin, 5-OH, Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours (h).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "2.23", 
                                                            "@value": "5.86"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "2.17", 
                                                            "@value": "5.38"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "T-HALF for Saxagliptin"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "3.06", 
                                                            "@value": "15.9"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "2.97", 
                                                            "@value": "17.0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "T-HALF for 5-OH Saxagliptin"
                                            }
                                        ]
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours (h).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Half-life (T-HALF) of Saxagliptin, and 5-OH Saxagliptin From Single Dose 5 mg Saxagliptin Versus T-HALF of Saxagliptin and 5-OH From Co-administered Saxagliptin With 10 mg Dapagliflozin - PK Evaluable Population", 
                                    "units": "h"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Half-life (T-HALF) of Saxagliptin, and 5-OH Saxagliptin From Single Dose 5 mg Saxagliptin Versus T-HALF of Saxagliptin and 5-OH From Co-administered Saxagliptin With 10 mg Dapagliflozin - PK Evaluable Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Saxagliptin is the parent drug and 5-OH saxagliptin is the metabolite. The molecular weights to be used for the molar ratios were 315.42 and 331.42 for saxagliptin and 5-OH, respectively.  Plasma samples were analyzed for saxagliptin and for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL and 0.200 ng/mL to 100.0 ng/mL for saxagliptin and 5-OH, respectively).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg Dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "5 mg Saxagliptin + 10 mg Dapagliflozin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "37", 
                                                            "@value": "1.90"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "37", 
                                                            "@value": "2.16"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "MR_Cmax"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "33", 
                                                            "@value": "2.92"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "33", 
                                                            "@value": "3.19"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "MR_AUC(INF)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "33", 
                                                            "@value": "2.89"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "34", 
                                                            "@value": "3.16"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "MR_AUC(0-T)"
                                            }
                                        ]
                                    }, 
                                    "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Saxagliptin is the parent drug and 5-OH saxagliptin is the metabolite. The molecular weights to be used for the molar ratios were 315.42 and 331.42 for saxagliptin and 5-OH, respectively.  Plasma samples were analyzed for saxagliptin and for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL and 0.200 ng/mL to 100.0 ng/mL for saxagliptin and 5-OH, respectively).", 
                                    "dispersion": "Geometric Coefficient of Variation", 
                                    "param": "Geometric Mean", 
                                    "title": "Metabolite to Parent Molar Ratios (MR) of Cmax, AUC(INF), and AUC(0-T) of 5-OH Saxagliptin and Saxagliptin From a Single Dose 5 mg Saxagliptin Versus MR of Saxagliptin and 5-OH When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable", 
                                    "units": "Molar ratio"
                                }
                            ]
                        }, 
                        "population": "PK Evaluable Population: All participants who received at least 1 dose of any study drug and had at least 1 valid PK parameter for at least 1 analyte.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 (0h to 60h post dose) in each period", 
                        "title": "Metabolite to Parent Molar Ratios (MR) of Cmax, AUC(INF), and AUC(0-T) of 5-OH Saxagliptin and Saxagliptin From a Single Dose 5 mg Saxagliptin Versus MR of Saxagliptin and 5-OH When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Adverse event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.  Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. End of study was approximately 16 days and was the time for a participant to conclude each of the 3 periods (including the 6 day washout between periods).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A:  Single dose oral tablet of 5 mg saxagliptin..", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment B:  A single oral tablet dose of 10 mg Dapagliflozin.", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Treatment C: Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin..", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "6"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "9"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "8"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Participants with AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "4"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "4"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "7"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Participants with treatment-related AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Participants with SAEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Participants discontinuing due to AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Deaths"
                                            }
                                        ]
                                    }, 
                                    "description": "Adverse event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.  Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. End of study was approximately 16 days and was the time for a participant to conclude each of the 3 periods (including the 6 day washout between periods).", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Deaths, Serious Adverse Events, Adverse Events, or Discontinuations Due to Adverse Events - Safety Population", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1 to end of study (16 days)", 
                        "title": "Number of Participants With Deaths, Serious Adverse Events, Adverse Events, or Discontinuations Due to Adverse Events - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal (LLN); upper limit of normal (ULN); pretreatment(pre-RX); treatment (RX). Hemoglobin (g/L): <0.85* pre-RX; hematocrit (vol): <0.85*pre-RX; erythrocytes (*10^12 c/L): <0.85*pre-RX; platelet count (*10^9 c/L): <0.85*LLN if pre-RX>=LLN, or if Pre-Tx <LLN; leukocytes (*10^9 c/L): <0.85*LLN if pre-RX <LLN,or <0.9*LLN if LLN<=Pre-RX<=ULN; neutrophils+bands (*10^9 c/L): <0.85*Pre-RX if Pre-RX <1.5 or <1.5 if Pre-RX >=1.5; eosinophils (*10^9 c/L): if value >0.75;  basophils (*10^9 c/L): if value >0.4; monocytes (*10^9c/L): if value >2; lymphocytes (*10^9 c/L): if value <0.750 or if value >7.50.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "A single oral tablet dose of 10 mg Dapagliflozin.", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet 5mg saxagliptin.", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Leukocytes Low"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Neutrophils (absolute) Low"
                                            }
                                        ]
                                    }, 
                                    "description": "Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal (LLN); upper limit of normal (ULN); pretreatment(pre-RX); treatment (RX). Hemoglobin (g/L): <0.85* pre-RX; hematocrit (vol): <0.85*pre-RX; erythrocytes (*10^12 c/L): <0.85*pre-RX; platelet count (*10^9 c/L): <0.85*LLN if pre-RX>=LLN, or if Pre-Tx <LLN; leukocytes (*10^9 c/L): <0.85*LLN if pre-RX <LLN,or <0.9*LLN if LLN<=Pre-RX<=ULN; neutrophils+bands (*10^9 c/L): <0.85*Pre-RX if Pre-RX <1.5 or <1.5 if Pre-RX >=1.5; eosinophils (*10^9 c/L): if value >0.75;  basophils (*10^9 c/L): if value >0.4; monocytes (*10^9c/L): if value >2; lymphocytes (*10^9 c/L): if value <0.750 or if value >7.50.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Marked Hematology Laboratory Abnormalities - Safety Population", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to Day 1 of each period", 
                        "title": "Number of Participants With Marked Hematology Laboratory Abnormalities - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Blood pressure was taken while the participant was quietly seated for at least 5 minutes. Blood pressure was measured in millimeters of mercury (mmHg). Baseline was Day -1 in Period 1; study drug was administered on Day 1 of each crossover period.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single dose oral tablet of 10 mg dapagliflozin.", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet 5mg saxagliptin.", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "7.41", 
                                                            "@value": "-6.0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "8.13", 
                                                            "@value": "-4.6"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@spread": "8.35", 
                                                            "@value": "-7.2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Systolic Blood Pressure"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@spread": "4.94", 
                                                            "@value": "-2.6"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@spread": "4.86", 
                                                            "@value": "-2.0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@spread": "6.23", 
                                                            "@value": "-3.3"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Diastolic Blood Pressure"
                                            }
                                        ]
                                    }, 
                                    "description": "Blood pressure was taken while the participant was quietly seated for at least 5 minutes. Blood pressure was measured in millimeters of mercury (mmHg). Baseline was Day -1 in Period 1; study drug was administered on Day 1 of each crossover period.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mean Change From Baseline in Systolic and Diastolic Blood Pressure - Safety Population", 
                                    "units": "mmHg"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to Day 1 of each period", 
                        "title": "Mean Change From Baseline in Systolic and Diastolic Blood Pressure - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Heart rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in beats per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single dose oral tablet of 10 mg dapagliflozin.", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet 5mg saxagliptin.", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "7.04", 
                                                        "@value": "-4.4"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "9.64", 
                                                        "@value": "-4.0"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "10.52", 
                                                        "@value": "-4.3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Heart rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in beats per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mean Change From Baseline in Heart Rate - Safety Population", 
                                    "units": "bpm"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to Day 1 in each period", 
                        "title": "Mean Change From Baseline in Heart Rate - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Respiration rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in breaths per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single dose oral tablet of 10 mg dapagliflozin.", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet 5mg saxagliptin.", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "3.46", 
                                                        "@value": "-0.4"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "2.89", 
                                                        "@value": "-1.2"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "3.13", 
                                                        "@value": "-0.9"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Respiration rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in breaths per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mean Change From Baseline in Respiration Rate - Safety Population", 
                                    "units": "bpm"
                                }
                            ]
                        }, 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to Day 1 in each period", 
                        "title": "Mean Change From Baseline in Respiration Rate - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participant had their temperature taken after quietly sitting for at least 5 minutes and it was measured as degrees of centigrade (C). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single dose oral tablet of 10 mg dapagliflozin.", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet 5mg saxagliptin.", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.393", 
                                                        "@value": "-0.15"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "0.383", 
                                                        "@value": "-0.23"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@spread": "0.385", 
                                                        "@value": "-0.16"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Participant had their temperature taken after quietly sitting for at least 5 minutes and it was measured as degrees of centigrade (C). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Mean Change From Baseline in Temperature - Safety Population", 
                                    "units": "degrees of centigrade"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to Day 1 in each period", 
                        "title": "Mean Change From Baseline in Temperature - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal(LLN); upper limit of normal (ULN); pre-treatment(Pre-Rx). Alkaline phosphatase U/L:>1.25*Pre-RX if Pre-Rx >ULN or >1.25*ULN if Pre-Rx <=ULN; aspartate aminotransferase (AST) U/L: >1.25*Pre-Rx if Pre-Rx > ULN or 1.25*ULN if Pre-Rx <= ULN;alanine aminotransferase (ALT) U/L: >1.25*Pre-Rx if Pre-Rx>ULN or 1.25*ULN if Pre-Rx<=ULN;blood urea nitrogen (BUN)mmol/L: >1.1*ULN if Pre-Rx <=ULN or >1.2*Pre-Rx if Pre-Rx >ULN; total bilirubin \u00b5mol/L: >1.1*ULN if Pre-Rx <=ULN or >1.25*Pre-Rx if Pre-Rx >ULN;direct bilirubin \u00b5mol/L: >1.1*ULN if Pre-Rx <= ULN or >1.25*Pre-Rx if Pre-Rx > ULN; creatine phosphokinase (CK) U/L: >1.5*Pre-Rx if Pre-Rx >ULN or >1.5*ULN if Pre-Rx <= ULN.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single dose oral tablet of 10 mg dapagliflozin", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet of 5mg saxagliptin.", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Total Bilirubin High"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Direct Bilirubin High"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "ALT High"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "BUN High"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "CK High"
                                            }
                                        ]
                                    }, 
                                    "description": "Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal(LLN); upper limit of normal (ULN); pre-treatment(Pre-Rx). Alkaline phosphatase U/L:>1.25*Pre-RX if Pre-Rx >ULN or >1.25*ULN if Pre-Rx <=ULN; aspartate aminotransferase (AST) U/L: >1.25*Pre-Rx if Pre-Rx > ULN or 1.25*ULN if Pre-Rx <= ULN;alanine aminotransferase (ALT) U/L: >1.25*Pre-Rx if Pre-Rx>ULN or 1.25*ULN if Pre-Rx<=ULN;blood urea nitrogen (BUN)mmol/L: >1.1*ULN if Pre-Rx <=ULN or >1.2*Pre-Rx if Pre-Rx >ULN; total bilirubin \u00b5mol/L: >1.1*ULN if Pre-Rx <=ULN or >1.25*Pre-Rx if Pre-Rx >ULN;direct bilirubin \u00b5mol/L: >1.1*ULN if Pre-Rx <= ULN or >1.25*Pre-Rx if Pre-Rx > ULN; creatine phosphokinase (CK) U/L: >1.5*Pre-Rx if Pre-Rx >ULN or >1.5*ULN if Pre-Rx <= ULN.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Marked Chemistry Laboratory Abnormalities - Safety Population", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to Day 1 in each period", 
                        "title": "Number of Participants With Marked Chemistry Laboratory Abnormalities - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Fasted for 10 hours prior to samples taken. LLN=lower limit of normal; ULN=upper limit of normal; pretreatment (Pre-Rx). Normals: Urine glucose qualitative: dipstick >=1 if Pre-Rx <1 or 2*Pre-Rx if Pre-Rx>=1; urine microscopic white blood cell count (WBC): >=2 if Pre-Rx <2 or >=4 if Pre-Rx >=2;urine red blood cell count (RBC):>=2 if Pre-Rx <2 or >=4 if Pre-Rx >=2.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Single dose oral tablet of 5 mg saxagliptin.", 
                                    "title": "Treatment A: Saxagliptin 5mg"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Single dose oral tablet of 10 mg dapagliflozin", 
                                    "title": "Treatment B: Dapagliflozin 10mg"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Co-administration of a single dose oral tablet of 10 mg dapagliflozin plus a single dose of oral tablet 5mg saxagliptin.", 
                                    "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "42"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "42"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "2"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "5"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Urine Glucose High (N=42, 42, 42)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "1"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Urine WBC and RBC High (N= 4, 8, 6)"
                                            }
                                        ]
                                    }, 
                                    "description": "Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Fasted for 10 hours prior to samples taken. LLN=lower limit of normal; ULN=upper limit of normal; pretreatment (Pre-Rx). Normals: Urine glucose qualitative: dipstick >=1 if Pre-Rx <1 or 2*Pre-Rx if Pre-Rx>=1; urine microscopic white blood cell count (WBC): >=2 if Pre-Rx <2 or >=4 if Pre-Rx >=2;urine red blood cell count (RBC):>=2 if Pre-Rx <2 or >=4 if Pre-Rx >=2.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Marked Urinalysis Laboratory Abnormalities - Safety Population", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug. Urine WBC and RBC were not done for all 42 participants. Number of participants analyzed (N) for the 3 treatments for WBC/RBC urine were 4, 8, 6, in treatment A, B, C, respectively.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to Day 1 of each period", 
                        "title": "Number of Participants With Marked Urinalysis Laboratory Abnormalities - Safety Population", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "A 12-Lead electrocardiogram (ECG) was performed and recorded after the participant had been supine for at least 5 minutes.  ECGs done at baseline (Day-1 of Period 1) and at end of study; therefore the results are presented by sequence, and cannot be presented by treatment. QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec). Abnormality criteria: QT/QTcF QT or QTcF >450 msec and <=480 msec at any postdose time point and not present at baseline. QT or QTcF >480 msec and <=500 msec at any postdose time point and not present at baseline QT or QTcF >500 msec at any postdose time point and not present at baseline. QT/QTcF Increase from baseline >60 msec for at least 1 postdose measurement. Increase from baseline in QT or QTcF >30 msec for at least 1 postdose measurement, but <=60 msec for all postdose measurements.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral.", 
                                    "title": "A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral.", 
                                    "title": "A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O3", 
                                    "description": "Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral", 
                                    "title": "B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)"
                                }, 
                                {
                                    "@group_id": "O4", 
                                    "description": "Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral.", 
                                    "title": "B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin"
                                }, 
                                {
                                    "@group_id": "O5", 
                                    "description": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets,Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral.", 
                                    "title": "C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin"
                                }, 
                                {
                                    "@group_id": "O6", 
                                    "description": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral.", 
                                    "title": "C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "7"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "7"
                                                    }, 
                                                    {
                                                        "@group_id": "O3", 
                                                        "@value": "7"
                                                    }, 
                                                    {
                                                        "@group_id": "O4", 
                                                        "@value": "7"
                                                    }, 
                                                    {
                                                        "@group_id": "O5", 
                                                        "@value": "7"
                                                    }, 
                                                    {
                                                        "@group_id": "O6", 
                                                        "@value": "7"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O4", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O5", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O6", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "QT change from baseline >60 msec"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "4"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O4", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O5", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O6", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "QT change from baseline >30 msec; <=60 msec"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O4", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O5", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O6", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "QTcF change from baseline >60 msec"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O3", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O4", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O5", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O6", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "QTcF change from baseline >30 msec; <=60 msec"
                                            }
                                        ]
                                    }, 
                                    "description": "A 12-Lead electrocardiogram (ECG) was performed and recorded after the participant had been supine for at least 5 minutes.  ECGs done at baseline (Day-1 of Period 1) and at end of study; therefore the results are presented by sequence, and cannot be presented by treatment. QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec). Abnormality criteria: QT/QTcF QT or QTcF >450 msec and <=480 msec at any postdose time point and not present at baseline. QT or QTcF >480 msec and <=500 msec at any postdose time point and not present at baseline QT or QTcF >500 msec at any postdose time point and not present at baseline. QT/QTcF Increase from baseline >60 msec for at least 1 postdose measurement. Increase from baseline in QT or QTcF >30 msec for at least 1 postdose measurement, but <=60 msec for all postdose measurements.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Change From Baseline in ECG Interval - Safety Population", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Safety Population = All participants who received at least one dose of any study drug.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline to end of study (16 days)", 
                        "title": "Number of Participants With Change From Baseline in ECG Interval - Safety Population", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "Single dose of:\nTreatment A: Saxagliptin 5mg, Tablet, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral", 
                            "title": "A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "Single dose of:\nTreatment A: Saxagliptin 5mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral", 
                            "title": "A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin"
                        }, 
                        {
                            "@group_id": "P3", 
                            "description": "Single dose of:\nTreatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral", 
                            "title": "B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)"
                        }, 
                        {
                            "@group_id": "P4", 
                            "description": "Single dose of:\nTreatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral", 
                            "title": "B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin"
                        }, 
                        {
                            "@group_id": "P5", 
                            "description": "Single dose of:\nTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment A: Saxagliptin 5mg, Tablet, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral", 
                            "title": "C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin"
                        }, 
                        {
                            "@group_id": "P6", 
                            "description": "Single dose of:\nTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; Treatment B: Dapagliflozin 10mg, Tablet, Oral; Treatment A: Saxagliptin 5mg, Tablet", 
                            "title": "C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin"
                        }
                    ]
                }, 
                "period_list": {
                    "period": [
                        {
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Period 1"
                        }, 
                        {
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Period 2"
                        }, 
                        {
                            "drop_withdraw_reason_list": {
                                "drop_withdraw_reason": {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "1", 
                                                "@group_id": "P2"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P3"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P4"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P5"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P6"
                                            }
                                        ]
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }
                            }, 
                            "milestone_list": {
                                "milestone": [
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "STARTED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "#text": "Participant did not provide 36, 48, or 60 hour samples in this period for Treatment B.", 
                                                    "@count": "6", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "7", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "COMPLETED"
                                    }, 
                                    {
                                        "participants_list": {
                                            "participants": [
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P1"
                                                }, 
                                                {
                                                    "@count": "1", 
                                                    "@group_id": "P2"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P3"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P4"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P5"
                                                }, 
                                                {
                                                    "@count": "0", 
                                                    "@group_id": "P6"
                                                }
                                            ]
                                        }, 
                                        "title": "NOT COMPLETED"
                                    }
                                ]
                            }, 
                            "title": "Period 3"
                        }
                    ]
                }, 
                "pre_assignment_details": "89 participants enrolled; 42 randomized and treated with study drug. 47 not randomized for following reasons: 3 withdrew consent, 38 no longer met study criteria, 6 had other reasons. Treatment was administered on Day 1 of each period after fast of 10 hours; Washout began after single dose in the period and was for at least 6 days.", 
                "recruitment_details": "20 August 2012 to 29 November 2012. Phase 1 Clinical Pharmacology center with healthy, fasted participants."
            }, 
            "point_of_contact": {
                "email": "Clinical.Trials@bms.com", 
                "name_or_title": "Bristol-Myers Squibb Study Director", 
                "organization": "Bristol-Myers Squibb"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Saxagliptin 5mg, Tablet, Oral, Once daily, 1 day in each of 3 periods.", 
                            "title": "Treatment A: Saxagliptin 5mg"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Dapagliflozin 10mg, Tablet, Oral, Once daily, 1 day in each of 3 periods.", 
                            "title": "Treatment B: Dapagliflozin 10mg"
                        }, 
                        {
                            "@group_id": "E3", 
                            "description": "Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, Once daily, 1 day in each of 3 periods.", 
                            "title": "Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "42"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Constipation"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Nausea"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Abdominal distension"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Abdominal pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Abdominal Pain Lower"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Toothache"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Vomiting"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Fatigue"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Pain"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "42"
                                            }
                                        ], 
                                        "sub_title": "ALT increased"
                                    }
                                }, 
                                "title": "Investigations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Back pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Pain in extremity"
                                        }
                                    ]
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "42"
                                            }
                                        ], 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "42"
                                            }, 
                                            {
                                                "@group_id": "E3", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "42"
                                            }
                                        ], 
                                        "sub_title": "Dysmenorrhea"
                                    }
                                }, 
                                "title": "Reproductive system and breast disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Oropharyngeal pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Cough"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Epistaxis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Nasal congestion"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "42"
                                                }, 
                                                {
                                                    "@group_id": "E3", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "42"
                                                }
                                            ], 
                                            "sub_title": "Rhinorrhoea"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 15.1", 
                    "frequency_threshold": "1"
                }, 
                "time_frame": "Day -1 to end of study (approximately 16 days). Total length of 3 crossover periods."
            }
        }, 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects as determined by no clinically significant deviation from normal in\n             medical history, Physical Examination, vital signs, 12-lead ECG, and clinical\n             laboratory determinations\n\n          -  Body mass index (BMI) of 18 to 30 kg/m2\n\n          -  Men and women, ages 18 to 45 years\n\n          -  Women of childbearing potential must use acceptable methods of highly effective birth\n             control\n\n        Exclusion Criteria:\n\n          -  History of chronic or recurrent urinary tract infection for females\n\n          -  History of allergies or adverse reactions to Dipeptidyl peptidase-IV (DPP4) or\n             Sodium-glucose transporter type 2 (SGLT2) inhibitors\n\n          -  Any significant acute or chronic medical illness\n\n          -  Current or recent gastrointestinal disease\n\n          -  Any major surgery within 4 weeks of study drug administration\n\n          -  Prior exposure to saxagliptin or dapagliflozin or related drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "firstreceived_results_date": "November 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662999", 
            "org_study_id": "CV181-191"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)", 
                    "A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin", 
                    "B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)", 
                    "B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin", 
                    "C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin", 
                    "C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin"
                ], 
                "intervention_name": "Saxagliptin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Onglyza\u00ae", 
                    "BMS-477118"
                ]
            }, 
            {
                "arm_group_label": [
                    "A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)", 
                    "A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin", 
                    "B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)", 
                    "B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin", 
                    "C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin", 
                    "C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin"
                ], 
                "intervention_name": "Dapagliflozin", 
                "intervention_type": "Drug", 
                "other_name": "BMS-512148"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Saxagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 31, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68154"
                }, 
                "name": "Icon Clinical Pharmacology"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Single-dose, Open-label, Randomized, 3 Period, 3 Treatment Crossover Study to Evaluate the Pharmacokinetics of Saxagliptin 5 mg and Dapagliflozin 10 mg When Coadministered to Fasted Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The geometric mean of the maximum observed plasma concentration (Cmax) is presented below; serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h,and 60 h postdose, relative to dosing on Day 1 in each cross over period and these data are summarized in the Pharmacokinetic (PK) parameter of Cmax presented here. Plasma samples were analyzed for dapagliflozin by High Performance Liquid chromatography-Mass Spectrometry (HPLC-MS/MS) using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Dapagliflozin Cmax was derived from plasma concentration versus time data using a non-compartmental method, using a validated PK analysis program \u2122. Actual sampling times were used for PK calculations. Cmax was reported in ng/mL.", 
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0 h to 60 h post dose) in each period"
            }, 
            {
                "description": "AUC(INF) is area under the plasma concentration-time curve from time 0 extrapolated to infinity. Serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL).   Actual sampling times were used for PK calculations. AUC(INF) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                "measure": "Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method).  Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL).  Actual sampling times were used for PK calculations. AUC(0-T) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                "measure": "Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). Cmax for Saxagliptin was derived from plasma concentration versus time data using a validated PK analysis program \u2122 and was measured in nanograms per milliliter (ng/mL).", 
                "measure": "Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(0-T), the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                "measure": "AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                "measure": "AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.   Actual sampling times were used for PK calculations. Tmax was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours.", 
                "measure": "Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.   Actual sampling times were used for PK calculations. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours.", 
                "measure": "Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method.  Actual sampling times were used for PK calculations. CLT/F was calculated as Dose/AUC(INF)and was measured in milliliters per minute  (mL/min).", 
                "measure": "Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). Actual sampling times were used for PK calculations. Cmax for 5-OH Saxagliptin (the major active metabolite of Saxagliptin) was derived from plasma concentration versus time data using a validated PK analysis program \u2122 and was measured in ng/mL.", 
                "measure": "Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method)and was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program \u2122. AUC (0-T) was measured in nanograms*hours per milliliter (ng*h/mL).", 
                "measure": "AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in nanograms*hours per milliliter (ng*h/mL).", 
                "measure": "AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Cmax of saxagliptin total active moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin) was derived from the plasma concentration versus time profile for the saxagliptin total active moiety.  Measurement was in nano Molars (nM).", 
                "measure": "Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. AUC(INF) is area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) and both were derived from the plasma concentration versus time profile using a validated PK analysis program \u2122. Total moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin), AUC(0-T)and AUC(INF) were measured in nano Molars*hours (nM*h).", 
                "measure": "AUC(INF) and AUC(0-T) of the Saxagliptin Total Active Moiety From a Single Dose 5 mg Saxagliptin Versus AUC(INF) and AUC(0-T) of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin and 5-OH by LC-MS/MS using a validated method. Tmax was derived from the plasma concentration versus time profile for study drug and was measured in hours (h). Saxagliptin was the drug, 5-OH saxagliptin was the metabolite, and Saxagliptin total Active Moiety was molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin.", 
                "measure": "Tmax of Saxagliptin, 5-OH Saxagliptin, Saxagliptin Total Active Moiety From a Single Dose of Saxagliptin Versus Tmax of Saxagliptin, 5-OH, Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program \u2122 and was measured in hours (h).", 
                "measure": "Half-life (T-HALF) of Saxagliptin, and 5-OH Saxagliptin From Single Dose 5 mg Saxagliptin Versus T-HALF of Saxagliptin and 5-OH From Co-administered Saxagliptin With 10 mg Dapagliflozin - PK Evaluable Population", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Saxagliptin is the parent drug and 5-OH saxagliptin is the metabolite. The molecular weights to be used for the molar ratios were 315.42 and 331.42 for saxagliptin and 5-OH, respectively.  Plasma samples were analyzed for saxagliptin and for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL and 0.200 ng/mL to 100.0 ng/mL for saxagliptin and 5-OH, respectively).", 
                "measure": "Metabolite to Parent Molar Ratios (MR) of Cmax, AUC(INF), and AUC(0-T) of 5-OH Saxagliptin and Saxagliptin From a Single Dose 5 mg Saxagliptin Versus MR of Saxagliptin and 5-OH When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (0h to 60h post dose) in each period"
            }, 
            {
                "description": "Adverse event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.  Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. End of study was approximately 16 days and was the time for a participant to conclude each of the 3 periods (including the 6 day washout between periods).", 
                "measure": "Number of Participants With Deaths, Serious Adverse Events, Adverse Events, or Discontinuations Due to Adverse Events - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to end of study (16 days)"
            }, 
            {
                "description": "Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal (LLN); upper limit of normal (ULN); pretreatment(pre-RX); treatment (RX). Hemoglobin (g/L): <0.85* pre-RX; hematocrit (vol): <0.85*pre-RX; erythrocytes (*10^12 c/L): <0.85*pre-RX; platelet count (*10^9 c/L): <0.85*LLN if pre-RX>=LLN, or if Pre-Tx <LLN; leukocytes (*10^9 c/L): <0.85*LLN if pre-RX <LLN,or <0.9*LLN if LLN<=Pre-RX<=ULN; neutrophils+bands (*10^9 c/L): <0.85*Pre-RX if Pre-RX <1.5 or <1.5 if Pre-RX >=1.5; eosinophils (*10^9 c/L): if value >0.75;  basophils (*10^9 c/L): if value >0.4; monocytes (*10^9c/L): if value >2; lymphocytes (*10^9 c/L): if value <0.750 or if value >7.50.", 
                "measure": "Number of Participants With Marked Hematology Laboratory Abnormalities - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 1 of each period"
            }, 
            {
                "description": "Blood pressure was taken while the participant was quietly seated for at least 5 minutes. Blood pressure was measured in millimeters of mercury (mmHg). Baseline was Day -1 in Period 1; study drug was administered on Day 1 of each crossover period.", 
                "measure": "Mean Change From Baseline in Systolic and Diastolic Blood Pressure - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 1 of each period"
            }, 
            {
                "description": "Heart rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in beats per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                "measure": "Mean Change From Baseline in Heart Rate - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 1 in each period"
            }, 
            {
                "description": "Respiration rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in breaths per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                "measure": "Mean Change From Baseline in Respiration Rate - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 1 in each period"
            }, 
            {
                "description": "Participant had their temperature taken after quietly sitting for at least 5 minutes and it was measured as degrees of centigrade (C). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.", 
                "measure": "Mean Change From Baseline in Temperature - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 1 in each period"
            }, 
            {
                "description": "Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal(LLN); upper limit of normal (ULN); pre-treatment(Pre-Rx). Alkaline phosphatase U/L:>1.25*Pre-RX if Pre-Rx >ULN or >1.25*ULN if Pre-Rx <=ULN; aspartate aminotransferase (AST) U/L: >1.25*Pre-Rx if Pre-Rx > ULN or 1.25*ULN if Pre-Rx <= ULN;alanine aminotransferase (ALT) U/L: >1.25*Pre-Rx if Pre-Rx>ULN or 1.25*ULN if Pre-Rx<=ULN;blood urea nitrogen (BUN)mmol/L: >1.1*ULN if Pre-Rx <=ULN or >1.2*Pre-Rx if Pre-Rx >ULN; total bilirubin \u00b5mol/L: >1.1*ULN if Pre-Rx <=ULN or >1.25*Pre-Rx if Pre-Rx >ULN;direct bilirubin \u00b5mol/L: >1.1*ULN if Pre-Rx <= ULN or >1.25*Pre-Rx if Pre-Rx > ULN; creatine phosphokinase (CK) U/L: >1.5*Pre-Rx if Pre-Rx >ULN or >1.5*ULN if Pre-Rx <= ULN.", 
                "measure": "Number of Participants With Marked Chemistry Laboratory Abnormalities - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 1 in each period"
            }, 
            {
                "description": "Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Fasted for 10 hours prior to samples taken. LLN=lower limit of normal; ULN=upper limit of normal; pretreatment (Pre-Rx). Normals: Urine glucose qualitative: dipstick >=1 if Pre-Rx <1 or 2*Pre-Rx if Pre-Rx>=1; urine microscopic white blood cell count (WBC): >=2 if Pre-Rx <2 or >=4 if Pre-Rx >=2;urine red blood cell count (RBC):>=2 if Pre-Rx <2 or >=4 if Pre-Rx >=2.", 
                "measure": "Number of Participants With Marked Urinalysis Laboratory Abnormalities - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Day 1 of each period"
            }, 
            {
                "description": "A 12-Lead electrocardiogram (ECG) was performed and recorded after the participant had been supine for at least 5 minutes.  ECGs done at baseline (Day-1 of Period 1) and at end of study; therefore the results are presented by sequence, and cannot be presented by treatment. QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec). Abnormality criteria: QT/QTcF QT or QTcF >450 msec and <=480 msec at any postdose time point and not present at baseline. QT or QTcF >480 msec and <=500 msec at any postdose time point and not present at baseline QT or QTcF >500 msec at any postdose time point and not present at baseline. QT/QTcF Increase from baseline >60 msec for at least 1 postdose measurement. Increase from baseline in QT or QTcF >30 msec for at least 1 postdose measurement, but <=60 msec for all postdose measurements.", 
                "measure": "Number of Participants With Change From Baseline in ECG Interval - Safety Population", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to end of study (16 days)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}